Histiocytic disorders are a rare and complex group of diseases characterized by the abnormal accumulation and activation of histiocytes, which are immune cells involved in inflammatory responses and tissue repair.
While individually uncommon, histiocytic disorders collectively affect patients worldwide and can involve multiple organ systems.
Among the most recognized subtypes are Langerhans cell histiocytosis (LCH), hemophagocytic lymphohistiocytosis (HLH), Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD). Epidemiological data suggest that LCH affects approximately two to five children per million annually, while HLH has an estimated incidence of one in 50,000 to 100,000 births, highlighting the diagnostic complexity and clinical burden associated with these rare immune-mediated conditions.
Executive Director
Histiocytosis Association
Advances in genomic research have also revealed that several histiocytic disorders are linked to mutations affecting MAPK pathway signaling, helping to inform emerging targeted treatment approaches.
Amid ongoing advances in the understanding of histiocytic disorders, the Histiocytosis Association has become an important global resource connecting patients, clinicians and researchers.
In an interview with Xtalks, Jen Silvers, MBA, CFRE, Executive Director of the Histiocytosis Association, reflected on the organization’s mission, priorities and the challenges facing the global histiocytosis community.
From Personal Advocacy to Global Impact
Founded in 1986 by parents seeking information and support following their child’s diagnosis with LCH, the Histiocytosis Association has grown into a globally recognized advocacy organization.
Silvers described the organization’s evolution over four decades, noting that it began when “no one knew anything about the disease. There were no resources, there was no information.” Today, the association supports patients and families around the world and is widely regarded as a first point of contact for those newly diagnosed.
Its mission is centered on raising awareness about histiocytic disorders, providing educational and emotional support and funding research leading to better treatments and ultimately a cure.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Enabling Early-Stage Research Through Seed Funding
Rather than conducting research directly, the Association focuses on catalyzing scientific progress through targeted funding programs. Each year, the organization issues a call for grant proposals and awards seed grants of approximately $50,000 to early-stage investigators.
Silvers explained that these grants are reviewed by a scientific committee and approved by a board that includes clinicians, researchers and individuals affected by histiocytosis. Typically, the association funds four to five projects annually, spanning multiple disease areas including HLH, LCH, Erdheim-Chester disease and Rosai-Dorfman disease.
These seed grants often serve as a stepping stone for researchers seeking larger funding opportunities. As Silvers noted, this approach helps ensure that “research is being done in all areas” of histiocytic disorders, supporting broader advances across the field.
Persistent Barriers to Diagnosis and Long-Term Care
Despite scientific progress, patients continue to face significant challenges. One of the most pressing issues is delayed diagnosis.
According to Silvers, histiocytic disorders can be difficult to recognize because many clinicians have never encountered them, and symptoms frequently resemble those of more common diseases. Increasing physician awareness is therefore critical to improving diagnostic timelines and treatment outcomes.
Another key issue is the transition of care from pediatric to adult healthcare systems. Many patients are diagnosed in childhood, but identifying adult specialists with expertise in histiocytosis can be challenging. Silvers highlighted that this transition remains a major concern within the patient community and advocacy space.
Expanding Awareness Through Community Engagement
Operating with a small but highly committed team, the Histiocytosis Association relies heavily on its global network of patients, families, clinicians and volunteers to raise awareness.
Silvers described the organization as “small but mighty,” emphasizing the importance of ambassadors and community advocates — many of whom are patients or caregivers — in driving fundraising and educational initiatives.
The association also collaborates closely with the Histiocyte Society, an international network of more than 200 physicians specializing in histiocytic disorders. Through these partnerships, the organization helps disseminate new research findings, treatment developments and clinical guidance.
To broaden outreach, the association uses newsletters, social media and its monthly podcast, Beyond the Diagnosis, which features discussions with clinicians, researchers and patients navigating rare disease journeys.
A core message guiding these efforts is reassurance for newly diagnosed individuals. As Silvers explained, “when you’re diagnosed with any rare disease, it feels like you’re on an island… we want people to know you are not alone.”
Supporting Global Collaboration and Access to Expertise
Beyond public education, the association maintains strong connections with international advocacy organizations and healthcare professionals.
Through regular virtual meetings and ongoing communication with clinicians worldwide, the organization helps patients identify specialized providers and access reliable information. Its Physician Finder and clinical trial listings serve as important tools for connecting patients with emerging treatment opportunities and expert care.
Opportunities for the Life Sciences Community
Silvers underscored the role that clinicians, researchers and industry stakeholders can play in advancing the Association’s mission. Increasing awareness among healthcare providers can improve referral pathways, ensuring patients receive both specialized medical care and access to support resources.
She also highlighted the importance of sharing information about ongoing research and clinical trials, noting that the association tracks these developments on its website to help inform patients and clinicians alike.
Expanding Research Investment in 2026
As the Histiocytosis Association marks its 40th anniversary, fundraising and research expansion remain key priorities.
Silvers said the organization aims to double annual general donations from approximately $200,000 to $400,000, enabling it to increase the number of research grants awarded each year.
By expanding funding capacity from four or five projects annually to potentially seven or eight, the association hopes to accelerate progress toward improved therapies and ultimately a cure.
For patients living with rare histiocytic disorders, these efforts represent continued momentum toward earlier diagnosis, better treatment pathways and stronger global support networks.
Join or login to leave a comment
JOIN LOGIN